Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 1;6(1):5.
doi: 10.1186/1758-2946-6-5.

The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation

Affiliations

The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation

Pedro Franco et al. J Cheminform. .

Abstract

Background: In the European Union, medicines are authorised for some rare disease only if they are judged to be dissimilar to authorised orphan drugs for that disease. This paper describes the use of 2D fingerprints to show the extent of the relationship between computed levels of structural similarity for pairs of molecules and expert judgments of the similarities of those pairs. The resulting relationship can be used to provide input to the assessment of new active compounds for which orphan drug authorisation is being sought.

Results: 143 experts provided judgments of the similarity or dissimilarity of 100 pairs of drug-like molecules from the DrugBank 3.0 database. The similarities of these pairs were also computed using BCI, Daylight, ECFC4, ECFP4, MDL and Unity 2D fingerprints. Logistic regression analyses demonstrated a strong relationship between the human and computed similarity assessments, with the resulting regression models having significant predictive power in experiments using data from submissions of orphan drug medicines to the European Medicines Agency. The BCI fingerprints performed best overall on the DrugBank dataset while the BCI, Daylight, ECFP4 and Unity fingerprints performed comparably on the European Medicines Agency dataset.

Conclusions: Measures of structural similarity based on 2D fingerprints can provide a useful source of information for the assessment of orphan drug status by regulatory authorities.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Three training-set molecule-pairs with the corresponding fractions (n= 143) of Yes/No responses to the question “Are these molecules similar?” The similarity values in the right-hand column are those obtained using the Tanimoto coefficient and ECFP4 fingerprints.
Figure 2
Figure 2
Distribution of expert assessments on the training-set.
Figure 3
Figure 3
Plot of the proportion of experts who assessed a training-set molecule-pair as being similar against the ECFP4 similarity for that molecule-pair. The figure also shows the computed logistic regression curve (and 95% confidence limits) for this fingerprint.
Figure 4
Figure 4
ROC curve for ECFP4 fingerprints.

Similar articles

Cited by

References

    1. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100:4–17. doi: 10.1016/j.healthpol.2010.12.002. - DOI - PubMed
    1. Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17:660–664. doi: 10.1016/j.drudis.2012.02.005. - DOI - PubMed
    1. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11:267–268. doi: 10.1038/nrd3654. - DOI - PubMed
    1. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010;9:921–928. doi: 10.1038/nrd3275. - DOI - PubMed
    1. Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N’Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, Lhoir A, Todorova M, Kkolos I, Kubáčková K, Bosch-Traberg H, Tillmann V, Saano V, Héron E, Elbers R, Siouti M, Eggenhofer J, Salmon P, Clementi M, Krieviņš D, Matulevičiene A, Metz H. et al.European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10:341–349. - PubMed